論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort.
掲載誌名	正式名：Clinical rheumatology 略　 称：Clin Rheumatol ISSNコード：14349949/07703198
掲載区分	国外
巻・号・頁	pp.Online ahead of print
著者・共著者	Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Takaaki Noguchi, Koichi Murata, Takayuki Fujii, Iku Shirasugi, Mai Yamashita, Koji Nagai, Ayaka Yoshikawa, Motomu Hashimoto, Tadashi Okano, Yuji Nozaki, Tetsu Itami, Yonsu Son, Hidehiko Makino, Wataru Yamamoto, Atsushi Kumanogoh, Seiji Okada, Ken Nakata, Kosuke Ebina
発行年月	2026/04
概要	OBJECTIVES:In Japan, pharmacological treatment for rheumatoid arthritis (RA), including biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi), is provided by both orthopaedic surgeons and rheumatologists. However, differences in patient characteristics, treatment selection, and outcomes between these two clinical settings have not been fully elucidated. This study aimed to compare these factors using real-world data.METHODS:Using the ANSWER cohort, we identified 7268 RA treatment courses initiating bDMARDs or JAKi between August 2002 and May 2023. Patients were classified into orthopaedic surgeon-managed and rheumatologist-managed groups. Patient characteristics and treatment patterns were compared. Treatment retention due to ineffectiveness and adverse events was assessed using Cox proportional hazards models to estimate hazard ratios (HRs) adjusted for potential confounders.RESULTS:Compared with the rheumatologist-managed group, patients managed by orthopaedic surgeons had longer disease duration, higher seropositivity, greater functional impairment, although lower comorbidity prevalence such as hypertension, dyslipidemia, and diabetes mellitus. Methotrexate, tumor necrosis factor inhibitors, JAKi, and intra-articular injections were used more frequently, whereas oral glucocorticoids were used less frequently. After adjustment, treatment retention due to ineffectiveness was comparable between groups (HR 0.98, 95% CI 0.83-1.17), and changes in disease activity were similar. Discontinuation due to adverse events was significantly less frequent in the orthopaedic surgeon-managed group (HR 0.61, 95% CI 0.46-0.82).CONCLUSIONS:Despite differences in patient profiles and treatment patterns, molecular-targeted therapy managed by orthopaedic surgeons achieved comparable effectiveness and was associated with a lower risk of discontinuation due to adverse events compared with rheumatology care. Key Points • Patients managed by orthopaedic surgeons had longer disease duration, higher seropositivity, and more advanced structural and functional impairment than those managed by rheumatologists. • Despite these differences, treatment effectiveness and disease activity improvement with bDMARDs or JAK inhibitors were comparable between specialties after adjustment for confounders. • Treatment discontinuation due to adverse events was less frequent in patients managed by orthopaedic surgeons. • Guideline-based management may enable consistent clinical outcomes across different specialties in real-world rheumatoid arthritis care.
DOI	10.1007/s10067-026-08061-7
PMID	41920235